MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) Files An 8-K Entry into a Material Definitive Agreement

MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) Files An 8-K Entry into a Material Definitive Agreement

Story continues below


Entry into a Material Definitive Agreement.

On May2, 2017, Miragen Therapeutics, Inc., a Delaware corporation
(the Company), entered into a fifth amendment (the Amendment) to
that certain license and collaboration agreement (the Servier
Agreement) between the Company and Les Laboratoires Servier and
the Institut de Recherches Servier (Servier).

Among other things, the Amendment removes the three existing
targets under the Servier Agreement and adds a new target,
microRNA-92, and provides Servier with (i)an exclusive license to
research, develop, and commercialize MRG-110, the Companys
product candidate that targets microRNA-92 for the treatment of
diseases through revascularization, in all countries, other than
the United States and Japan where the Company retains all rights,
as if microRNA-92 were an original target under the Servier
Agreement, and (ii)the right to obtain such an exclusive license
for another target to be named by Servier no later than
September30, 2019. Additionally, the Amendment extends the term
of the research collaboration between the Company and Servier
until September30, 2019 or the date of completion of the agreed
upon research activities, whichever is later. Under the terms of
the Amendment, Servier agreed to reimburse the Company for a
specified amount of the costs associated with the manufacture and
production of the MRG-110 drug product when the drug product is
delivered and ready for use, and the Company agreed to be
responsible for a specified amount of the pre-Phase 3 costs that
it incurs under the Servier Agreement in the third quarter of
2017. Servier also agreed to pay the Company a one-time milestone
at a specified amount upon the earlier of the completion of a
specified development goal or November15, 2017.

As a result of the Amendment, Serviers rights to the three
removed targets and product candidates directed to such removed
targets are terminated and returned to the Company.

The foregoing description of the Amendment is not complete and is
qualified in its entirety by reference to the full text of the
Amendment. The Company anticipates filing a copy of the Amendment
with its periodic report on Form 10-Q for the quarter ended
June30, 2017.

On May3, 2017, the Company issued a press release announcing the
effectiveness of the Amendment. A copy of the press release is
filed herewith as Exhibit 99.1 and incorporated by reference

Item9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.


99.1 Press release, dated May 3, 2017.


Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.


MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) closed its last trading session 00.00 at 12.30 with 38,761 shares trading hands.

An ad to help with our costs